Cart
sales@molnova.com
Erythromycin estolate
CAS No. 3521-62-8
Erythromycin estolate( —— )
Catalog No. M33353 CAS No. 3521-62-8
Erythromycin estolate
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 50MG | 31 | In Stock |
|
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 111 | In Stock |
|
| 1G | 163 | In Stock |
|
Biological Information
-
Product NameErythromycin estolate
-
NoteResearch use only, not for human use.
-
Brief DescriptionErythromycin estolate
-
DescriptionErythromycin estolate, erythromycin derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3521-62-8
-
Formula Weight1056.39
-
Molecular FormulaC52H97NO18S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (94.66 mM; Ultrasonic )
-
SMILESCCCCCCCCCCCCOS(O)(=O)=O.CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2OC(=O)CC)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. David E. Kleiner, et al. Learn more about Erythromycin Estolate. Biomaterials and Medical Device - Associated Infections, 2015
molnova catalog
related products
-
TBA-354
TBA-354 is a novel antitubercular agent that shows MIC of 6 uM against M. tuberculosis H37Rv.
-
Walrycin-B
A novel baterial WalR response regulator; simultaneously affects the expression of WalR regulon genes.
-
6-Sialyllactose Sodi...
6'-Sialyllactose Sodium Salt (6'-N-Acetylneuraminyl-D-lactose sodium salt), an oligosaccharide present in breast milk, is protective against LPS-induced ALI and attenuates LPS-induced lung injury by inhibiting the STAT1 and NF-κB signaling pathways. Diquat dibromide
